Skip to main content

Entadfi FDA Approval History

Last updated by Judith Stewart, BPharm on Dec 13, 2021.

FDA Approved: Yes (First approved December 9, 2021)
Brand name: Entadfi
Generic name: finasteride and tadalafil
Dosage form: Capsules
Company: Veru Inc.
Treatment for: Benign Prostatic Hyperplasia

Entadfi (finasteride and tadalafil) is a 5α-reductase inhibitor and phosphodiesterase 5 (PDE5) inhibitor combination indicated for the treatment of urinary tract symptoms caused by benign prostatic hyperplasia (BPH).

Development timeline for Entadfi

DateArticle
Dec 13, 2021Approval FDA Approves Entadfi (finasteride and tadalafil) as a New Treatment for Benign Prostatic Hyperplasia

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.